Because of a large body of literature describing EMT as a major cause of chemotherapy resistance2,22 and because our data suggest that targeting of netrin-1 inhibits EMT, we assessed whether the addition of NP137 to carboplatin-paclitaxel (carbotaxol), the standard-of-care chemotherapy used in clinical settings in endometrial cancer, might enhance the efficacy of carbotaxol alone in the Pten f/f mouse model of endometrial adenocarcinoma. The gene discussed is NTN1; the disease is endometrial cancer.